In re HeartWare International, Inc. Securities Litigation

Track this case

Case Number:

1:16-cv-00520

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Ronnie Abrams

Firms

Companies

Sectors & Industries:

  1. March 12, 2019

    Bernstein Litowitz Seeks $13M In Atty Fees In Medtronic Case

    Bernstein Litowitz Berger & Grossmann LLP asked a New York federal judge Monday to approve $13 million in attorneys' fees as part of a $54.5 million class action settlement of investors' claims that Medtronic unit HeartWare International misled them about a new heart pump's prospects.

  2. November 16, 2018

    Medtronic Unit Agrees To $54.5M Deal In Investor Fraud Suit

    Medtronic PLC unit HeartWare International told a Manhattan federal court on Friday that it will pay $54.5 million to investors to settle allegations that it misled them about the prospects of its MVAD heart pump and overstated its efforts to fix problems with the device.

  3. March 16, 2018

    Stock-Drop Suit Targeting HeartWare Survives Dismissal Bid

    A Manhattan judge declined to toss a fraud action targeting medical device maker HeartWare International Inc. Friday, holding that former workers, who said the company didn't come clean about problems with its flagship heart pump product, gave plausibility to claims that investors were misled.

  4. August 31, 2016

    HeartWare Says Investor Suit Over FDA Regs Is 'Opportunistic'

    A shareholder suit against HeartWare International Inc. over a new heart pump product is "opportunistic" and based entirely on implausible inferences drawn from hindsight after a clinical trial failed, the company said Tuesday, urging a New York federal judge to toss the suit.

  5. January 25, 2016

    Investor Says HeartWare Lied About FDA Compliance

    An investor in HeartWare International Inc. hit the company with a derivative suit in New York federal court on Friday, claiming that the heart pump maker's failure to comply with U.S. Food and Drug Administration safety regulations led to a product redesign and caused its stock price to fall 70 percent.